The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-escalation study of chemoradiotherapy of three-dimensional conformal radiotherapy (3D-CRT) with accelerated hyperfractionation (AHF) and concurrent chemotherapy (cisplatin and vinorelbine) for unresectable stage III non-small cell lung cancer (NSCLC).
N. Yoshimura
No relevant relationships to disclose
S. Kudoh
No relevant relationships to disclose
H. Tanaka
No relevant relationships to disclose
N. Sizumira
No relevant relationships to disclose
T. Kimura
No relevant relationships to disclose
S. Mitsuoka
No relevant relationships to disclose
T. Tada
No relevant relationships to disclose
M. H. Hosono
No relevant relationships to disclose
K. Hirata
No relevant relationships to disclose